This approach not only alleviated the reduction of T cell proliferation and cytotoxic activity induced by the binding of tumor cell PD‐L1 to T cell PD‐1, but also inhibited the excessive proliferation of tumor cells triggered by the activation of the EGFR pathway via ligands such as EGF and amphiregulin. This evidence concerns the gene EGFR and neoplasm.